Aytu BioPharma Inc AYTU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AYTU is a good fit for your portfolio.
News
-
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
-
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
-
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
-
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Trading Information
- Previous Close Price
- $2.84
- Day Range
- $2.88–2.92
- 52-Week Range
- $1.38–3.50
- Bid/Ask
- $2.72 / $2.90
- Market Cap
- $16.17 Mil
- Volume/Avg
- 6,144 / 21,611
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.14
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 150
- Website
- https://www.aytubio.com
Valuation
|
Metric
|
AYTU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.49 |
Price/Sales | 0.14 |
Price/Cash Flow | 3.09 |
Price/Earnings
AYTU
Financial Strength
|
Metric
|
AYTU
|
|---|---|
Quick Ratio | 0.76 |
Current Ratio | 1.11 |
Interest Coverage | −23.53 |
Quick Ratio
AYTU
Profitability
|
Metric
|
AYTU
|
|---|---|
Return on Assets (Normalized) | −6.73% |
Return on Equity (Normalized) | −24.29% |
Return on Invested Capital (Normalized) | −15.22% |
Return on Assets
AYTU
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Rksjfnby | Xxxt | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Lklzzllkl | Kwkwsl | $70.8 Bil | |
HLN
| Haleon PLC ADR | Tlkbvqsm | Kwnd | $38.2 Bil | |
VTRS
| Viatris Inc | Jnghylyj | Wckg | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Xydcpjm | Vnrnx | $12.5 Bil | |
CTLT
| Catalent Inc | Zbznxhsqc | Zrcdgq | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Rqrhwfg | Hjg | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Dfdvcbg | Lmw | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Zchtksvf | Fkfmxt | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Zgbqdfxfvc | Rdnr | $2.9 Bil |